Searchable abstracts of presentations at key conferences in endocrinology

ea0047oc33 | Spotlight on Prostate Cancer | Theranostics2016

Molecular imaging with 64Cu-PSMA PET/CT in Theranostics of prostate cancer

Singh Aviral , Kulkarni Harshad , Baum Richard P.

Objectives: Copper-64 (64Cu, T1/2=12.7 h; Eβ+ max =0.65 MeV (17.9%); Eβ− max =0.57 MeV (39%)) is suitable for in-vivo PET imaging. Prostate specific membrane antigen (PSMA) is significantly over-expressed in undifferentiated prostate cancer tissue. We report the initial molecular imaging results with 64Cu-PSMA PET/CT in patients with prostate cancer.Methods: 64Cu labeled PSMA (mean administered ra...

ea0047oc32 | Spotlight on Prostate Cancer | Theranostics2016

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Kulkarni Harshad R. , Singh Aviral , Schuchardt Christiane , Niepsch Karin , Baum Richard P.

Aim: To analyze the safety, efficacy and dosimetry of Lu-177 labeled prostate specific membrane antigen (PSMA) ligand 617 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC), in comparison with Lu-177 PSMA I&T.Methods: Lu-177 PSMA-617 radioligand therapy (PRLT) was performed in 64 mCRPC patients. The median administered activity per treatment was 6 GBq. Ga-68 PSMA PET/CT was used for patient selection and follow-up. H...

ea0047oc15 | Spotlight on Neuroendocrine tumours | Theranostics2016

Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large series of paragangliomas

Kaemmerer Daniel , Saenger Joerg , Arsenic Ruza , D'Haese Jan G. , Neumann Jens , Singh Aviral , Baum Richard P. , Schulz Stefan , Lupp Amelie

Background: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed.Aims: In the present study the expression of the five somatostatin receptor (SSTR) subtypes as well as of the chemokine receptor CXCR4 and of the endothelin receptor A (ETA) was e...

ea0060p14 | (1) | UKINETS2018

Circulating neuroendocrine tumor gene expression is effective in monitoring peptide receptor radionuclide (PRRT) efficacy

Bodei Lisa , Kidd Mark , van der Zwan Wouter , Singh Aviral , Severi Stefano , Drozdov Ignat , Cwikla Jarowslaw , Kolasinska-Cwikla Agnieska , Baum Richard , Paganelli Giovanni , Krenning Eric , Modlin Irvin

Background: Predicting and monitoring PRRT is based upon NET overexpression of somatostatin receptor (SSR) to deliver targeted isotope therapy. Imaging SSR expression is ~60% accurate as a predictor of efficacy. However, it and other imaging modalities e.g., CT/MRI, have utility for monitoring response. Specific blood NET gene expression (Positive Predictor Quotient- [PPQ]) is accurate in predicting PRRT response (93–97%, Bodei et al. EJNMMI 2018). The utility of NET tran...

ea0052oc1 | (1) | UKINETS2017

A predictive quotient index, comprising neuroendocrine gene cluster analysis in blood and tissue grading is specifically predicts PRRT efficacy

Bodei Lisa , Kidd Mark , van der Zwaan Wouter , Singh Aviral , Severi Stefano , Drozdov Ignat , Kwekkeboom Dik , Cwikla Jaroslaw , Kolasinska-Cwikla Agnieska , Baum Richard P , Paganelli Giovanni , Krenning Eric , Modlin Irvin M

Background: The efficacy of PRRT is based upon NET over expression of somatostatin receptor (SSR) to deliver targeted isotope therapy. SSR expression (Krenning scale) compared to Predictive Quotient Index (PQI) (circulating NET transcript analysis mathematically integrated with grade) indicates the latter is more accurate for predicting PRRT efficacy. We evaluated whether PQI was specifically predictive or was prognostic for PRRT compared to other therapeutic strategi...